Value and the pricing of innovation
Location: Level 0, Konrad Adenauer Saal
Balancing the cost of innovation and ensuring access to high-quality, effective medical treatment continues to be a challenge for all modern healthcare systems. Significant shifts in global and local market dynamics, policy and politics are prompting a discussion about other dimensions of value, be they economic, social, or scientific. Different markets are at different stages of this discussion. While some countries in Europe already have mechanisms in place to assess drugs within an established framework of measures, others are grappling with workable systems of assessment and their repercussions. Can these forerunners inform the discussion in other geographies? How can biotech innovators best demonstrate the value of their therapies so that outcomes are measurable and relevant to all stakeholders? These and other questions will be discussed by our panel of experts.
Senior VP, International Affairs,
Biotechnology Innovation Organization (BIO)
SV Life Sciences Advisers
Member, Executive Committee Pharmaceuticals Division and Head of Development,
Director, Institute for Quality and Efficiency in Health Care,